Business
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC) has been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22 – 26, 2025, at the Hynes Convention Center in Boston, Massachusetts. ATNM-400 is a highly innovative, first-i
About this update from Actinium Pharmaceuticals, Inc. (delaware)
[{"type":"list","items":[{"val":[{"type":"text","content":"ATNM-400 is advancing as a first-in-class, multi-tumor Actinium-225 radiotherapy candidate with activity across prostate and lung cancers, two of the largest cancer indications globally","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"New preclinical findings demonstrate ATNM-400 overcomes resistance to the EGFR inhibitor osimertinib in EGFR-mutated NSCLC, addressing a major unmet clinical need","length":167,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":352,"olType":false},{"type":"text","content":"NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC) has been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22 – 26, 2025, at the Hynes Convention Center in Boston, Massachusetts. ATNM-400 is a highly innovative, first-in-class, Actinium-225 (Ac-225) antibody radioconjugate with preclinical data in both prostate cancer and NSCLC. Together, these two indications represent more than 500,000 new cases annually in the U.S. alone.","length":754,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Actinium Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Actinium Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":97,"url":"https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yUttGl4ecQ0sM9T7v.HK4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747","width":400,"height":97}},"href":"https://mma.prnewswire.com/media/730678/Actinium_Pharmaceuticals_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"ATNM-400 in NSCLC: Addressing Resistance to EGFR TKIs","length":53,"tagName":"p","attribs":{}},{"type":"text","content":"NSCLC accounts for approximately 85% of lung cancer cases and remains the leading cause of cancer mortality worldwide. While EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib (TAG...